Groundbreaking Trial Links Fitness to Longer Life After Chemotherapy
Colon cancer, one of the most common cancers globally, has long been treated with surgery, chemotherapy, and medications. But a new, multi-country clinical trial has introduced a powerful, accessible tool into the fight: exercise.
Published in the New England Journal of Medicine and presented at the 2025 ASCO Annual Meeting, the CHALLENGE trial is the first randomized controlled trial to prove that regular, structured physical activity after chemotherapy significantly boosts survival rates and reduces cancer recurrence in colon cancer patients.
The CHALLENGE Trial: Design and Scope
Conducted over 15 years across 55 global centers, the CHALLENGE trial enrolled 889 patients with resected stage II or III colon cancer who had completed chemotherapy. Half of the participants received standard health education. The other half were placed into a structured, personalized 3-year exercise program.
This program included weekly coaching sessions during the first 6 months, then monthly follow-ups. Exercise types ranged from brisk walking and swimming to salsa classes and circuit training. Patients were encouraged to exceed general population activity guidelines—aiming for at least 3–4 sessions of 45–60 minutes per week.
The Numbers: Survival and Recurrence
The trial results were staggering. At 5 years:
- 80.3% of the exercise group remained disease-free
- 73.9% of the health education group remained disease-free
That’s a 28% reduction in cancer recurrence risk or development of new cancer in the exercise group.
At the 8-year mark:
- 90.3% of the exercise group were alive
- 83.2% of the health education group were alive
This corresponds to a 37% lower risk of death for those who followed the exercise plan.
Source: CHALLENGE Trial, New England Journal of Medicine (2025)
Exercise as Medicine: The Science Behind the Shift
Researchers still aren’t entirely sure why exercise works so effectively, but several mechanisms are under study:
- Lowered inflammation levels
- Reduced insulin-like growth factor (IGF-1), which fuels tumor growth
- Boosted immune surveillance against cancer cells
- Improved muscle mass and strength, helping recovery and resilience
Dr. Joe Henson of the University of Leicester explained, “Exercise not only lifted people’s mood and reduced fatigue, but we saw measurable improvements in immune system performance.”
Transforming Clinical Guidelines
Professor Vicky Coyle of Queen’s University Belfast, who co-led the study, emphasized that this represents a fundamental shift: “We must stop thinking of treatment as only medication or surgery. Exercise is treatment too.”
Cancer Research UK’s Caroline Geraghty added: “This trial can change clinical practice—if we fund and staff it appropriately.”
Beyond Colon Cancer: Broader Implications
The success of the CHALLENGE trial is already influencing research into other cancers:
- LEANer Trial (2023): Found that triple-negative breast cancer patients had a 53% higher treatment success rate with exercise and dietary intervention.
- Oesophageal Cancer Trial (2025): Showed stronger immune responses in patients who exercised during and after chemotherapy.
New studies, such as the Optimus Trial in the UK, aim to explore how muscle and fat tissues respond to physical activity in cancer survivors.
Comparison with Traditional Treatments
At the ASCO conference, a comparison chart highlighted that the 7–8% overall survival gains offered by some approved cancer therapies are matched—and even exceeded—by the 37% benefit shown in the exercise group.
MET Hours and Mortality Risk
The CHALLENGE trial focused on a 10 MET-hours/week target—roughly equivalent to 150 minutes of moderate activity.
World Cancer Research Fund’s CUP Global review showed that:
- A 10 MET-hour/week increase correlates with a 24% drop in all-cause mortality
Source: CUP Global Review, International Journal of Cancer (2024)
From “Nice to Have” to “Need to Have”
The oncology world is moving away from treating exercise as a side note. As Dr. Kerry Courneya, co-lead of CHALLENGE, put it: “We are leaving the ‘nice to have’ phase and entering the ‘need to have’ era for exercise in cancer care.”
Hospitals, insurance providers, and cancer clinics must now consider:
- Adding physical activity coaches to cancer treatment teams
- Using wearable activity trackers for monitoring and motivation
- Offering digital, at-home programs for patients who can’t attend gyms
Personal Voices: Real-Life Impact
Margaret Tubridy, a 69-year-old participant from Belfast, never exercised before joining the CHALLENGE trial. Five years post-diagnosis, she now does weight training, pole walking, and attends gym classes twice a week.
“I never imagined myself lifting weights at 69,” she says. “I’m stronger, fitter, and happier. The trial changed my life.”
Public Health and Policy Momentum
This study may encourage government bodies like the UK’s NHS, Australia’s Medicare, and Canada’s public healthcare to implement exercise prescriptions alongside cancer drugs.
Fitness companies like Peloton, Fitbit, or Apple Health could play a role in delivering patient-friendly programs. Brands such as Adidas, Nike, and Lululemon might partner with hospitals to promote survivorship through movement.
Final Thoughts
If you or a loved one is recovering from colon cancer, speak with your oncologist about adding exercise to the treatment plan. This isn’t about running marathons—just walking briskly a few times a week may make a life-saving difference.
This article is for informational purposes only and does not constitute financial advice. Readers are encouraged to do thorough research before making any investment decisions.
